Sustained release formulation of a non-steroidal anti-inflammatory drug
Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
1. A formulation of one or more non-steroidal anti-inflammatory drugs, comprising:
one or more non-steroidal anti-inflammatory drugs selected from the group consisting of meloxicam and piroxicam; and
multivesicular liposomes,
wherein the multivesicular liposomes comprise a first aqueous phase and a second aqueous phase;
wherein the one or more non-steroidal anti-inflammatory drugs are encapsulated in the first aqueous phase of the multivesicular liposomes; and
wherein the first aqueous phase comprises at least one pH modifier, said pH modifier comprises an organic acid or an organic base, or a combination thereof.
2. The formulation of claim 1 prepared by a process comprising:
providing a volume of first emulsion by mixing a first aqueous phase and a volatile water-immiscible solvent phase, said solvent phase comprising at least one amphipathic lipid and at least one neutral lipid, and said first aqueous phase comprising at least one pH modifier, said pH modifier comprises an organic acid or an organic base, or a combination thereof;
providing a volume of second emulsion comprising a continuous aqueous phase by mixing and emulsifying said first emulsion and a second aqueous phase;
removing the volatile water-immiscible solvent from the second emulsion to form a composition of multivesicular liposomal particles; and
remote loading one or more non-steroidal anti-inflammatory drugs into said multivesicular liposomes, wherein a gradient of low pH outside the multivesicular liposomes to high pH inside the multivesicular liposomes is present to drive the one or more non-steroidal anti-inflammatory drugs into the first aqueous phase of the multivesicular liposomes;
wherein the one or more non-steroidal anti-inflammatory drugs are selected from the group consisting of diclofenac, meloxicam and piroxicam.
3. The formulation of claim 2 , wherein the at least one pH modifier comprises lysine or glutamic acid, or a combination thereof.
4. The formulation of claim 3 , wherein the lysine or glutamic acid, or a combination thereof, is adjusted to a pH from about 4.7 to about 9.2.
5. The formulation of claim 2 , wherein the non-steroidal anti-inflammatory drug is piroxicam.
6. The formulation of claim 2 , wherein the non-steroidal anti-inflammatory drug is meloxicam.
7. The formulation of claim 2 , wherein the gradient is from about 1 to about 2 pH units.
8. The formulation of claim 1 prepared by a process comprising:
providing a volume of first emulsion by mixing at least one non-steroidal anti-inflammatory drug, a first aqueous phase and a volatile water-immiscible solvent phase, said solvent phase comprising at least one amphipathic lipid and at least one neutral lipid, and said first aqueous phase comprising at least one pH modifier, wherein said pH modifier comprises an organic acid or an organic base, or a combination thereof;
providing a volume of second emulsion comprising a continuous aqueous phase by mixing and emulsifying said first emulsion and a second aqueous phase; and
removing the volatile water-immiscible solvent from the second emulsion to form a composition of multivesicular liposomal particles;
wherein the one or more non-steroidal anti-inflammatory drugs are selected from the group consisting of meloxicam and piroxicam.
9. The formulation of claim 1 , wherein said non-steroidal anti-inflammatory drug is piroxicam.
10. The formulation of claim 1 , wherein said non-steroidal anti-inflammatory drug is meloxicam.
11. The formulation of claim 1 , wherein the at least one pH modifier further comprises an inorganic acid.
12. The formulation of claim 1 , wherein the at least one pH modifier further comprises an inorganic base.
13. The formulation of claim 1 , wherein the at least one pH modifier comprises lysine or glutamic acid, or a combination thereof.
14. The formulation of claim 1 , wherein the multivesicular liposomes comprise cholesterol, one or more phospholipids or salts thereof, and one or more triglycerides.
15. The formulation of claim 14 , wherein the phospholipid is selected from a phosphatidyl choline, a phosphatidyl glycerol and salts thereof, or a combination thereof.
16. The formulation of claim 15 , wherein the phosphatidyl glycerol is DPPG.
17. The formulation of claim 15 , wherein the phosphatidyl choline is DEPC.
18. The formulation of claim 14 , wherein the triglyceride is selected from triolein, tricaprylin, or a combination of the two.
19. The formulation of claim 1 , wherein the formulation is stable at 5° C. for at least 3 months.